Literature DB >> 16145193

An overview of psychotropic drug-drug interactions.

Neil B Sandson1, Scott C Armstrong, Kelly L Cozza.   

Abstract

The psychotropic drug-drug interactions most likely to be relevant to psychiatrists' practices are examined. The metabolism and the enzymatic and P-glycoprotein inhibition/induction profiles of all antidepressants, antipsychotics, and mood stabilizers are described; all clinically meaningful drug-drug interactions between agents in these psychotropic classes, as well as with frequently encountered nonpsychotropic agents, are detailed; and information on the pharmacokinetic/pharmacodynamic results, mechanisms, and clinical consequences of these interactions is presented. Although the range of drug-drug interactions involving psychotropic agents is large, it is a finite and manageable subset of the much larger domain of all possible drug-drug interactions. Sophisticated computer programs will ultimately provide the best means of avoiding drug-drug interactions. Until these programs are developed, the best defense against drug-drug interactions is awareness and focused attention to this issue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16145193     DOI: 10.1176/appi.psy.46.5.464

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  24 in total

Review 1.  Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.

Authors:  Richard D Boyce; Steven M Handler; Jordan F Karp; Joseph T Hanlon
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-27

Review 2.  [Drug interactions in geriatric medicine].

Authors:  Angela Storka; Johannes Pleiner
Journal:  Wien Med Wochenschr       Date:  2009

Review 3.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

4.  Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry.

Authors:  Woonhyoung Lee; Jeong-Ho Kim; Hyon-Suk Kim; Oh Hun Kwon; Byung In Lee; Kyoung Heo
Journal:  Neurol Sci       Date:  2010-12       Impact factor: 3.307

5.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

6.  Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.

Authors:  Dana Emmert; Christopher R Campos; David Ward; Peihua Lu; Hilda A Namanja; Kelsey Bohn; David S Miller; Frances J Sharom; Jean Chmielewski; Christine A Hrycyna
Journal:  ACS Chem Neurosci       Date:  2014-02-07       Impact factor: 4.418

7.  Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.

Authors:  Nathan L Sparkman; Ming Li
Journal:  Behav Pharmacol       Date:  2012-10       Impact factor: 2.293

8.  The role of pharmacotherapy in the management of self-regulation difficulties in young children.

Authors:  Pratibha N Reebye; Dean Elbe
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-05

Review 9.  Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.

Authors:  Mark Sanford; Lesley J Scott
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-03       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.